PortfoliosLab logoPortfoliosLab logo
BKRIY vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BKRIY vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bank of Ireland Group plc (BKRIY) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BKRIY achieves a 6.94% return, which is significantly higher than AZN's -2.12% return.


BKRIY

1D
-2.01%
1M
9.26%
YTD
6.94%
6M
9.69%
1Y
49.77%
3Y*
33.91%
5Y*
29.85%
10Y*

AZN

1D
-0.66%
1M
-3.91%
YTD
-2.12%
6M
-0.95%
1Y
26.16%
3Y*
9.19%
5Y*
11.73%
10Y*
14.81%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BKRIY vs. AZN - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BKRIY
Bank of Ireland Group plc
6.94%119.01%11.49%-1.02%62.51%46.84%-26.85%-1.91%-42.63%
AZN
AstraZeneca PLC
-2.12%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%9.93%

Correlation

The correlation between BKRIY and AZN is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.15

Correlation (All Time)
Calculated using the full available price history since Jan 23, 2018

0.07

The correlation between BKRIY and AZN shifts across timeframes, from 0.07 (all time) to 0.18 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

EPS

BKRIY:

$2.92

AZN:

$6.66

PE Ratio

BKRIY:

6.83

AZN:

26.48

PEG Ratio

BKRIY:

0.12

AZN:

0.04

PS Ratio

BKRIY:

2.35

AZN:

4.55

Total Revenue (TTM)

BKRIY:

$8.38B

AZN:

$60.44B

Gross Profit (TTM)

BKRIY:

$8.38B

AZN:

$49.37B

EBITDA (TTM)

BKRIY:

$2.06B

AZN:

$20.47B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BKRIY vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BKRIY
BKRIY Risk / Return Rank: 8181
Overall Rank
BKRIY Sharpe Ratio Rank: 8484
Sharpe Ratio Rank
BKRIY Sortino Ratio Rank: 7878
Sortino Ratio Rank
BKRIY Omega Ratio Rank: 7777
Omega Ratio Rank
BKRIY Calmar Ratio Rank: 8383
Calmar Ratio Rank
BKRIY Martin Ratio Rank: 8585
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 7070
Overall Rank
AZN Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7070
Sortino Ratio Rank
AZN Omega Ratio Rank: 6565
Omega Ratio Rank
AZN Calmar Ratio Rank: 7171
Calmar Ratio Rank
AZN Martin Ratio Rank: 7474
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BKRIY vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bank of Ireland Group plc (BKRIY) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BKRIYAZNDifference
Sharpe ratioReturn per unit of total volatility

+0.60

Sortino ratioReturn per unit of downside risk

+0.42

Omega ratioGain probability vs. loss probability

1.27

1.20

+0.07

Calmar ratioReturn relative to maximum drawdown

3.03

1.71

+1.32

Martin ratioReturn relative to average drawdown

8.66

4.70

+3.96

BKRIY vs. AZN - Sharpe Ratio Comparison

The current BKRIY Sharpe Ratio is 1.64, which is higher than the AZN Sharpe Ratio of 1.05. The chart below compares the historical Sharpe Ratios of BKRIY and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BKRIYAZNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

1.64

1.05

+0.60

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.73

0.49

+0.24

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.60

Sharpe Ratio (All Time)

Calculated using the full available price history

0.24

0.49

-0.25

Drawdowns

BKRIY vs. AZN - Drawdown Comparison

The maximum BKRIY drawdown since its inception was -86.27%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for BKRIY and AZN.


Loading charts...

Drawdown Indicators


BKRIYAZNDifference

Max Drawdown

Largest peak-to-trough decline

-86.27%

-48.94%

-37.33%

Max Drawdown (1Y)

Largest decline over 1 year

-16.51%

-15.43%

-1.08%

Max Drawdown (3Y)

Largest decline over 3 years

-25.37%

-27.87%

+2.50%

Max Drawdown (5Y)

Largest decline over 5 years

-31.02%

-27.87%

-3.15%

Max Drawdown (10Y)

Largest decline over 10 years

-27.87%

Current Drawdown

Current decline from peak

-2.44%

-15.43%

+12.99%

Average Drawdown

Average peak-to-trough decline

-29.77%

-11.37%

-18.40%

Ulcer Index

Depth and duration of drawdowns from previous peaks

5.77%

5.60%

+0.17%

Volatility

BKRIY vs. AZN - Volatility Comparison

Bank of Ireland Group plc (BKRIY) has a higher volatility of 8.71% compared to AstraZeneca PLC (AZN) at 6.36%. This indicates that BKRIY's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BKRIYAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

8.71%

6.36%

+2.35%

Volatility (6M)

Calculated over the trailing 6-month period

23.51%

17.06%

+6.45%

Volatility (1Y)

Calculated over the trailing 1-year period

30.43%

25.18%

+5.25%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

40.88%

23.94%

+16.94%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

48.77%

24.90%

+23.87%

Dividends

BKRIY vs. AZN - Dividend Comparison

BKRIY's dividend yield for the trailing twelve months is around 4.11%, more than AZN's 3.02% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
3.02%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
BKRIY
Bank of Ireland Group plc
4.11%3.14%11.28%2.53%0.57%0.00%0.00%2.36%1.76%0.00%0.00%0.00%

Financials

BKRIY vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Bank of Ireland Group plc and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B202120222023202420252026
1.90B
15.29B
(BKRIY) Total Revenue
(AZN) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BKRIY and AZN have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

BKRIY has higher volatility (8.71%) compared to AZN (6.36%). In terms of maximum drawdown, BKRIY dropped -86.27% vs AZN's -48.94%.

BKRIY currently has the higher Sharpe Ratio (1.64 vs 1.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BKRIY and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer